What is Immix Biopharma Probability of Financial Distress (%)?
Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Immix Biopharma's Probability of Financial Distress (%) is 0.27%.
Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.
Competitive Comparison of Immix Biopharma's Probability of Financial Distress (%)
For the Biotechnology subindustry, Immix Biopharma's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immix Biopharma's Probability of Financial Distress (%) Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immix Biopharma's Probability of Financial Distress (%) distribution charts can be found below:
* The bar in red indicates where Immix Biopharma's Probability of Financial Distress (%) falls into.
Immix Biopharma Probability of Financial Distress (%) Calculation
Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.
The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:
| LPFD | = | -20.12 * NIMTAAVG | + | 1.60 * TLMTA | - | 7.88 * EXRETAVG | + | 1.55 * SIGMA | - | 0.005 * RSIZE | - | 2.27 * CASHMTA | + | 0.070 * MB | - | 0.09 * PRICE | - | 8.87 |
| = | -5.91 |
The Probability of Financial Distress (%) (PFD) was then obtianed by:
| PFD | = | 1 | / | (1 + e^(-LPFD)) | * | 100% |
| = | 0.27% |
The eight explanatory variables are:
1. NIMTAAVG = Net Income to Market Total Assets
*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.
2. TLMTA = Total liabilities to Market Total Assets
3. CASHMTA = Cash to Market Total Assets
For non-financial companies, CASHMTA is measured as:
4. EXRETAVG = Excess Return compared to the S&P 500
EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.
5. SIGMA = Standard Deviation of Daily Returns
For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).
6. RSIZE = Relative Size
| RSIZE | = | log (Market Cap | / | Total Market Cap of S&P 500 companies) |
7. MB = Market to Adjusted Book Equity Ratio
8. PRICE
PRICE is measured as the log of the stock price, capped at log(15).
Immix Biopharma (Immix Biopharma) Business Description
Traded in Other Exchanges
N/A
Address
11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.
Executives
| Jason Hsu |
director |
11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064 |
| Carey Ng |
director |
11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064 |
| Helen C. Adams |
director |
15378 AVENUE OF SCIENCE, STE 100, SAN DIEGO CA 92128 |
| Melissa Jane Buchan |
director |
1920 MAIN STREET, SUITE 500, IRVINE CA 92614 |
| Magda Marquet |
director |
ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121 |
| Yekaterina Chudnovsky |
director, 10 percent owner |
C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210 |
| Ilya M Rachman |
director, officer: CEO and Chairman |
11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064 |
| Gabriel S Morris |
director, officer: Chief Financial Officer |
11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064 |
| Sean Senn |
10 percent owner |
11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064 |
| Vladimir P Torchilin |
officer: Scientific Co-Founder |
11400 WEST OLYMPIC BLVD.,, SUITE 200, LOS ANGELES CA 90064 |
| Graham Ross |
officer: CMO & Head of Clinical Dev. |
11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES CA 90064 |
Immix Biopharma (Immix Biopharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMMX has been successfully added to your